Allogene Therapeutics, Inc.

Based in South San Francisco, Allogene Therapeutics is a clinical-stage biotechnology company focused on developing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases. The company's primary approach involves creating "off-the-shelf" CAR-T cell products that can be manufactured from healthy donor cells and administered to multiple patients, potentially addressing manufacturing complexity and cost limitations associated with autologous cell therapies. Lead product candidates include UCART19 for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia and cemacabtagene ansegedleucel for large B-cell lymphoma.

The company's pipeline extends across multiple solid and hematologic malignancies. Clinical-stage programs target DLL3 in small cell lung cancer, Claudin 18.2 in gastric and pancreatic cancer, and FLT3 in acute myeloid leukemia, among other candidates. Allogene maintains strategic partnerships with major pharmaceutical companies including Pfizer and Servier, as well as research collaborations with The University of Texas MD Anderson Cancer Center and licensing agreements with Cellectis and Notch Therapeutics.

The company operates with approximately 226 full-time employees. As a pre-commercial clinical-stage enterprise, Allogene does not currently generate product revenue and relies on partnership agreements and capital resources to fund operations and development activities.